GoldenGolden
Advanced Search
Celularity

Celularity

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies.

Contents
Funding Venture round 1 Venture round 2
Timeline
Funding rounds
Products
Acquisitions
Patents
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies. Celularity is headquartered in Warren, New Jersey and was founded in 2016 by Carlos Ramirez, Jerome Zeldis, Jodi Gurney, John R Haines, Robert Hariri, and Steven French.

Funding
Venture round 1

On September 28, 2017 Celularity announced closing a venture round raising $40 million in capital from undisclosed investors.

Venture round 2

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins.

Timeline

February 15, 2018
Venture round 2

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins.

September 28, 2017
Venture round 1

On September 28, 2017 Celularity announced closing a venture round raising $40 million in capital from undisclosed investors.

2016
Founding of Celularity

Celularity is headquartered in Warren, New Jersey and was founded in 2016 by Carlos Ramirez, Jerome Zeldis, Jodi Gurney, John R Haines, Robert Hariri, and Steven French.

Funding rounds

Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration

Celularity

https://www.prnewswire.com/news-releases/celularity-announces-250m-in-funding-to-deliver-treatments-for-cancer-inflammatory-and-degenerative-diseases-and-functional-regeneration-300599589.html

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials
Gail Dutton
April 13, 2021
BioSpace
On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GX Acquisition Corp. - GXGX
Monteverde & Associates PC
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS...
Celularity to Present at the B. Riley Securities Virtual Oncology Investor Conference
Celularity
January 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular...
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
Celularity
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Celularity Inc. ("Celularity"), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of...
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 Study | BioSpace
December 1, 2020
BioSpace
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 Study - read this article along with other careers information, tips and advice on BioSpace
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 Study
Celularity, Inc.
December 1, 2020
www.prnewswire.com:443
/PRNewswire/ -- Celularity announced today that the independent Data Monitoring Committee (DMC) completed the first assessment of the ongoing Phase I/II...
Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in Adults with Recurrent Glioblastoma Multiforme (GBM)
BioSpace
November 24, 2020
BioSpace
Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today that the first patient was dosed in its Phase 1 clinical study of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) in adults with r
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
BioSpace
November 17, 2020
BioSpace
Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today the addition of two senior executives to its distinguished leadership team.

References

celularity.com
Is a
Company

Company attributes

Industry
Biotechnology
Cancer
Healthcare
Regenerative medicine
Stem cell
Location
Warren County, New Jersey
United States
Crunchbase
crunchbase.com/organiz...lularity
Investors
John Sculley
Tony Robbins
Andrew von Eschenbach
Bill Maris
Green D Ventures
Total funding amount (USD)
250,000,000
Latest funding round date
February 2018

Other attributes

Country
United States

Categories

Related Topics

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
OverviewPricingEnterprise
Legal
Terms & ConditionsCommercial Terms & ConditionsPrivacy Policy
Help
Help centerAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.